国际皮肤性病学杂志    2002 28 (2): 73-76   ISSN: 2096-5540  CN: 32-1880/R   新的免疫抑制剂——匹美克莫司 高建明, 陈志强 中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042 收稿日期 2001-09-21  修回日期 null  网络版发布日期 null 参考文献  [1] Paul C,Ho VC.Ascomycins in dermatology.Semin Cutan Med Surg,1998,17(4):256-259. [2] Grassberger M,Baumruker T,Enz A,et al.A novel anti-inflammatory drug,SDZ ASM 981,for the treatment of skin diseases:in vitro pharma-cology.Br J Dermatol,1999,141 (2):264-273. [3] Peterson LB,Cryan JG,Rosa R,et al.A tacrolimus-related immtmosup-pressant with biochemical properties distinct from those of tacrolimus.Transplantation,1998,65(1):10-18. [4] Van Leent EJ,Graber M,Thurston M,et al.Effectiveness of the as-comycin macrolactam SDZ ASM 981 in the topical treatment of atopic der-matitis.Arch Dermatol,1998,134(7):805-809. [5] Neckermann G,Bavandi A,Meingassner JG.Atopic dermatitis-like symp-toms in hypomagnesaemic hairless rats are prevented and inhibited by sys-temic or topical SDZ ASM 981.Br J Dermatol,2000,142(4):669-679. [6] Meingassner JG,Grassberger M,Fahrngruber H,et al.A novel anti-in-flammatory drug,SDZ ASM 981,for the topical and oral treatment of skin diseases:in vivo pharmacology.Br J Dermatol,1997,137(4):568-576. [7] Harper J,Green A,Scott G,et al.First experience of topical SDZ ASM 981 in children with atopic dermatitis.Br J Dertnatol,2001,144(4):781-787. [8] Queille-Roussel C,Paul C,Duteil L,et al.The new topical ascomycin derivative SDZ ASM 981 does not induce akin atrophy when applied to normal skin for 4 weeks:a randomized,double-blind controlled study.Br J Dermatol,2001,144(3):507-513. [9] Mrowietz U,Graeber M,Brautigam M,et al.The novel ascomycin deriva-tive SDZ ASM 981 is effective for psoriasis when used topically under oc-clusion.Br J Dermatol,1998,139:992-996. [10] Rappersberger K,Komar M,Ebelin ME,et al.Clinical experience with oral SDZ ASM 981 in psoriasis.J Eur Acad Dermatol Venereol,2000,14(Suppl 1):255. [11] Rappersberger K,Meingassner JG,FiaUa R,et al.Cleating of psoriasis by a novel immunosuppressive macrolide.J Invest Dermatol,1996,106(4):701-710. [12] Luger T,Van Leent EJ,Graeber M,et al.SDZ ASM 981:an emerging safe and effective treatment for atopie dermatitis.Br J Dermatol,2001,144(4):788-794. [13] Queille-Roussel C,Graeber M,Thurston M,et al.SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicit-ed by allergen challenge.Contact Dermatitis,2000,42(6):349-350. [14] eherill R,Tofte S,MaeNaul R,et al.SDZ ASM 981 1%cream is effective in the treatment of chronic irritant hand dermatitis.J Eur Aead Derm Venereol,2000,14(Suppl 1):128. [15] Mollison KW,Fey TA,Krause RA,et al.Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosup-pressant nephrotoxicity with a novel single-dase rat cisplatin potentiation assay.J Phannacol Exp Ther,1997,283(3):1509-1519. [16] Dtmont FJ,Koprak S,Staruch MJ,et al.A tacrolimus-related immano-suppressant with reduced toxicity.Transplantatien,1998,65 (1):18-26. [17] Mollison KW,Fey TA,Krause RA,et al.Nephrotoxicity studies of the im-munesuppressants tacrolimmus (FKS06) and ascomycin in rat models.Tox-icology,1998,125:169-181. [18] Mollison KW,Fey TA,Gauvin DM,et al.A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treat-ment of inflammatory skin diseases.J Invest Dermatol,1999,112(5):729-738. 通讯作者: